Home/Pipeline/IkT-001

IkT-001

Pulmonary Arterial Hypertension (PAH)

Phase 2Active - Phase in progress

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Phase 2

Status

Active - Phase in progress

Company

Inhibikase Therapeutics

About Inhibikase Therapeutics

Inhibikase Therapeutics is a clinical-stage biotech focused on developing selective kinase inhibitors, with its lead candidate IkT-001 targeting pulmonary arterial hypertension (PAH). The company's strategy is to improve upon the proven efficacy of imatinib in PAH by designing a molecule with a superior safety and tolerability profile. Led by a seasoned management team with deep cardiovascular and biopharmaceutical experience, Inhibikase is advancing its Phase 2 IMPROVE-PAH trial. The company went public via a SPAC merger in 2021 and is positioned in a high-need orphan disease market with significant unmet medical need.

View full company profile

Therapeutic Areas

Cardiopulmonary Disease Pulmonary Arterial Hypertension

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Transdermal Treprostinil Prodrug Patch	Corsair Pharma	Pre-clinical	Active
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Tiprelestat	tiakis Biotech	Phase 2	Active
Seralutinib	Chiesi	Phase 3	Active
Sotatercept	Merck	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
Beraprost MR	United Therapeutics	Phase 3	Active (ISABELA)
YUTREPIA™ (treprostinil) inhalation powder	Liquidia Corporation	Approved	Approved; Commercial preparation
LIQ861 (treprostinil) inhalation powder	Liquidia Corporation	Phase 3	Active
L606 (liposomal treprostinil) injection	Liquidia Corporation	Preclinical	Investigational